More lessons learned from the suffocation of hypoxia

Journal of Clinical Oncology

Volumn 28, Issue 18, 2010, Pages 2941-2943

  Ang, K Kian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOGEN; CISPLATIN; ETANIDAZOLE; FLUOROURACIL; MISONIDAZOLE; NICOTINAMIDE; NIMORAZOLE; TIRAPAZAMINE; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT;

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; EDITORIAL; HEAD AND NECK CARCINOMA; HYPERBARIC OXYGEN; MULTIPLE CYCLE TREATMENT; OROPHARYNX CARCINOMA; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; ANOXIA; CLINICAL TRIAL; HEAD AND NECK TUMOR; HUMAN; MULTIMODALITY CANCER THERAPY; NOTE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

ANOXIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RADIATION-SENSITIZING AGENTS;

EID: 77954612304     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.3085     Document Type: Editorial

References (18)

1. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and possible implications for radiotherapy. Br J Cancer 9:539, 1955
2. Rischin D, Peters LJ, O'Sullivan B, et al: Tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28:2989-2995, 2010
3. Peters LJ, O'Sullivan B, Giralt J, et al: Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: Results From TROG 02.02. J Clin Oncol 28:2996-3001, 2010
4. Overgaard J: Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 25:4066-4074, 2007
5. Kaanders JHAM, Bussink J, van der Kogel AJ: ARCON: A novel biology-based approach in radiotherapy. Lancet Oncol 3:728-737, 2002 (Pubitemid 35446742)
6. Overgaard J, Sand Hansen H, Overgaard M, et al: A randomized doubleblind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46:135-146, 1998 (Pubitemid 28109172)
7. Dorie M, Brown J: Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53:4633-4636, 1993 (Pubitemid 23304391)
8. Siim BG, Menke DR, Dorie MJ, et al: Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: Relationship to tumor hypoxia. Cancer Res 57:2922-2928, 1997 (Pubitemid 27315040)
9. Rischin D, Peters L, Hicks R, et al: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19:535-542, 2001 (Pubitemid 32112868)
10. Rischin D, Peters L, Fisher R, et al: Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79-87, 2005 (Pubitemid 41702625)
11. Tatum JL: Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82:699-757, 2006
12. Ibbott GS, Followill DS, Molineu HA, et al: Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials. Int J Radiat Oncol Biol Phys 71:S71-S75, 2008 (Pubitemid 351491444)
13. Le Q, Taira A, Budenz S, et al: Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas. Cancer 106:1940-1949, 2006
14. Rischin D, Hicks RJ, Fisher R, et al: Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24:2098-2104, 2006 (Pubitemid 46622121)
15. Lee N, Nehmeh S, Schöder H, et al: Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for headand- neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 75:101-108, 2009
16. Chaturvedi AK, Engels EA, Anderson WF, et al: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26:612-619, 2008 (Pubitemid 351264356)
17. Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261-269, 2008 (Pubitemid 351480538)
18. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus (HPV) and survival of patients with oropharynx cancer. N Engl J Med (in press)